Autism Committee Meet: REAL ID Required for In-Person Buzz
Published Date: 2/24/2026
Notice
Summary
The Interagency Autism Coordinating Committee is holding a free meeting on March 19, 2026, to talk about autism research and services. Anyone can join in person or online, but if you want to attend in person, you need to register ahead and bring a REAL ID. Public comments are welcome until March 5, so this is a great chance for the autism community to share their thoughts and stay in the loop.
Analyzed Economic Effects
6 provisions identified: 4 benefits, 1 costs, 1 mixed.
Free public autism committee meeting
The Interagency Autism Coordinating Committee is holding a free, public meeting on March 19, 2026, from 9:00 a.m. to 5:00 p.m. You can attend in person or watch online via NIH Videocast at no cost.
REAL ID required for in-person entry
If you plan to attend in person at the Neuroscience Center in Rockville, MD, you must pre-register and bring a REAL ID or equivalent at check-in. The notice states attendees will be asked to show government-issued photo ID and state the purpose of their visit.
Public comment deadline and record rules
Written public comments are due by 5:00 p.m. ET on Thursday, March 5, 2026, and all submitted comments become part of the public record. Comments received after 5:00 p.m. ET on March 5, 2026, may still be provided to the Committee before or after the meeting depending on processing time.
Limited 3-minute oral/virtual comment slots
A limited number of individuals may give approximately 3-minute oral or virtual summaries of their written comments during the meeting; indicate interest in your submission to be considered for a slot. Priority for slots will go to people or organizations that have not previously provided comments in the current calendar year.
Disability accommodations and captioning available
Closed captioning is provided through the NIH videocast, and people needing special assistance (e.g., sign language or interpreting services) must request accommodations from the listed contact at least seven (7) business days before the meeting. Last-minute accommodation requests may not be possible to fulfill.
Virtual participation via NIH Videocast
You can view the open session virtually via the NIH Videocast website (https://videocast.nih.gov/), and technical support is available via the provided email for webcast issues. Virtual viewing does not require in-person registration or ID.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2026-03683, Foreign-Trade Zone (FTZ) 183, Notification of Proposed Production Activity; Ultra Clean Technology Systems and Service, Inc.; (Inputs Primarily for Semiconductor Industry); Manor, Texas
Ultra Clean Technology Systems in Manor, Texas wants to start making special parts mainly for the semiconductor industry inside Foreign-Trade Zone 183. This means they can bring in certain materials from other countries and make products like tubing, valves, and machinery with some tax and customs benefits. The government got their request on February 17, 2026, and once approved, this could speed up production and save money.
Next: 2026-03685, Agency Information Collection Activities: Information Collection Renewal; Submission for OMB Review; Reg E-Prepaid Accounts
The Office of the Comptroller of the Currency (OCC) is renewing its paperwork for prepaid accounts under Reg E and asking for public comments by March 26, 2026. This update helps keep the rules clear and reduces unnecessary paperwork for banks and prepaid account providers. No big cost changes, but your feedback can shape how this info is collected going forward!